ANNEXON INC. - COMMON

Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

04 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

03 июн 2024 16:30:00 Источник Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

13 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

Annexon Biosciences to Present at the Bank of America Health Care Conference

09 май 2024 08:00:01 Источник Nasdaq GlobeNewswire

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

07 май 2024 12:30:00 Источник Nasdaq GlobeNewswire

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

01 май 2024 08:00:01 Источник Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

03 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

26 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

18 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

27 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

21 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

20 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

07 янв 2024 20:00:05 Источник Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

27 дек 2023 06:30:00 Источник Nasdaq GlobeNewswire

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

20 дек 2023 17:27:50 Источник Nasdaq GlobeNewswire

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

20 дек 2023 17:10:53 Источник Nasdaq GlobeNewswire

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

20 дек 2023 17:08:02 Источник Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 дек 2023 16:01:00 Источник Nasdaq GlobeNewswire